ZOVOO
10.12.2021 09:28:14 CET | Business Wire | Press release
ZOVOO , founded in 2019 and emerging as a dark horse in the electronic cigarette industry, recently launched its latest product Dragbar and achieved a sales milestone of over 1,000,000 pieces in the global market in less than one month, fully demonstrating the extraordinary strength of ZOVOO .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005123/en/
User-oriented and differentiated to meet market demand
According to ZOVOO' s global sales analysis, ZOVOO had an impressive performance in Southeast Asia, North America and Europe, which is attributable to not only Dragbar' s excellent capability, but also the ZOVOO team's in-depth and detailed market analysis of different regions.
Dragbar' s innovation and research team employed polymer fibers and ergonomic lip sensation design to address the consumers' most-concerned issues such as oil leakage and dry hit, while also ensuring the taste and recovery of the product. Using the most popular double injection molding process and the collision of extremely vibrant colors, the high-quality product is aesthetically attractive and tasteful, and soon gained the recognition of the consumers.
Product preference varies in different markets, so the team made in-depth investigations on product appearances and sizes and provided different series of Dragbar to cater to users in different regions, eventually achieving sales performance that was in line with the target of the ZOVOO team.
Creating amazing products with extreme craftsmanship
The ZOVOO design team, with its decade-long history, consists of senior creative elites, concept artists, visual designers and technical engineers. As ZOVOO 's first product for the overseas market, Dragbar cost the design team a whole year to finish. Even after thousands of adjustments, tests, and appearance improvements, the team did not start mass production until it was 100% confident with the final product.
In addition, since the founding of ZOVOO , the team has been focused on technology, constantly making breakthroughs and pursuing new patents and new technologies. During the long process ranging from research and development to design, production, and testing before the launch of each product, the innovation and research team is particular about every detail of the product, so as to bring comfortable and safe experience to the consumers.
Dragbar' s sales volume of 1,000,000 pieces achieved in a short period of time fully demonstrated the ZOVOO team's accurate insight into the users' needs, its excellent research and development capabilities, as well as its forward-looking product design strength. With the excellent performance of Dragbar, ZOVOO has successfully entered markets in more than 50 countries and regions in North America, Europe and Southeast Asia. In the future, the ZOVOO team will continue to develop new products in line with market trends to meet the users' new needs.
About ZOVOO
ZOVOO has established strategic partnerships with ICCPP manufacturers on a basis of mutual trust. ZOVOO enables its sustainable supply chain management by supporting safety standards, social values and environment-friendliness. With the motto of "Creating is Endless", ZOVOO is committed to adding inspirations to the colorful life of people with technology, and seeking partners globally to better serve the consumers.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical. The product is only intended for adult smokers of legal purchase age.
ZOVOO Official Website: https://www.izovoo.com/
IG: https://www.instagram.com/zovoo_tech/
Facebook: https://www.facebook.com/zovootechofficial
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005123/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
